Side Effects of Anagrelide
Anagrelide causes frequent cardiovascular and gastrointestinal side effects that require careful monitoring, with headache (44%), palpitations (26%), and diarrhea (26%) being the most common adverse reactions. 1
Most Common Side Effects (≥5% incidence)
Based on FDA-approved labeling from clinical trials of 942 patients with myeloproliferative neoplasms, the following adverse reactions occur most frequently 1:
Cardiovascular Effects
- Palpitations (26%) - most common cardiac side effect
- Tachycardia (8%)
- Chest pain (8%)
These cardiovascular effects result from anagrelide's direct vasodilating and positive inotropic properties as a phosphodiesterase-3 (PDE3) inhibitor 2, 3.
Neurological Effects
- Headache (44%) - the single most common adverse reaction
- Dizziness (15%)
- Paresthesia (6%)
Gastrointestinal Effects
- Diarrhea (26%)
- Nausea (17%)
- Abdominal pain (16%)
- Vomiting (10%)
- Flatulence (10%)
- Anorexia (8%)
- Dyspepsia (5%)
General/Constitutional Symptoms
- Asthenia/weakness (23%)
- Edema (21%) - includes peripheral edema (9%)
- Pain (15%)
- Fever (9%)
- Malaise (6%)
Respiratory Effects
- Dyspnea (12%)
- Cough (6%)
Other Common Effects
- Rash (8%)
- Pruritus (6%)
- Back pain (6%)
Serious Adverse Reactions
The most concerning serious adverse reactions involve cardiovascular complications 1:
- Congestive heart failure
- Myocardial infarction 4
- Cardiomyopathy
- Cardiomegaly
- Complete heart block
- Atrial fibrillation
- Cerebrovascular accident
- Pericardial effusion
- Supraventricular tachycardia 5
- Ventricular tachycardia
- Torsades de pointes (post-marketing)
Pulmonary Complications
- Pulmonary hypertension
- Pleural effusion
- Pulmonary infiltrates
- Pulmonary fibrosis
- Interstitial lung diseases (including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis) - post-marketing reports 1
Other Serious Events
- Pancreatitis
- Hepatotoxicity (symptomatic ALT/AST elevations >3× ULN) - post-marketing 1
- Tubulointerstitial nephritis - post-marketing 1
Treatment Discontinuation
Approximately 17% (161/942) of patients discontinued anagrelide due to adverse reactions or abnormal laboratory results 1. The most common reasons for discontinuation were:
- Headache
- Diarrhea
- Edema
- Palpitations
- Abdominal pain
Long-Term Safety Concerns
In a prospective 2-year study, side effects and toxic discontinuation rates were notably high 6:
- 50% of patients continued treatment after 2 years
- Side effects included palpitations (70%), headache (52%), nausea (35%), diarrhea/flatulence (33%), edema (22%), and fatigue (23%)
In young patients (<60 years) treated for over 10 years, anagrelide was associated with progressive anemia in CALR-mutated patients and new bone marrow fibrosis in JAK2-unmutated patients 7. This suggests limiting long-term use to JAK2-mutated patients with periodic monitoring for bone marrow fibrosis.
Less Common Adverse Reactions (1-5% incidence)
- Flu symptoms, chills
- Arrhythmia, angina pectoris, heart failure, syncope
- Hemorrhage, hypertension, postural hypotension, vasodilatation
- Constipation, gastrointestinal hemorrhage, gastritis
- Anemia, thrombocytopenia, ecchymosis
- Elevated liver enzymes
- Arthralgia, myalgia
- Depression, confusion, nervousness
- Somnolence, insomnia, amnesia, migraine
- Epistaxis, pneumonia
- Alopecia
- Abnormal vision, diplopia, tinnitus
- Hematuria, renal failure
Pediatric Considerations
The frequency of adverse reactions in pediatric patients is similar to adults 1. The most common pediatric adverse reactions include:
- Fever
- Epistaxis
- Headache
- Fatigue
- Episodes of increased pulse and decreased blood pressure (often asymptomatic)
Critical Monitoring Requirements
Given the side effect profile, patients on anagrelide require:
- Cardiovascular monitoring - especially for patients with pre-existing cardiac disease
- Avoid concomitant use with other PDE3 inhibitors (cilostazol, milrinone) or QT-prolonging drugs 8, 1
- Bleeding risk assessment - particularly when combined with aspirin or antiplatelet agents 1
- Hepatic and renal function monitoring - given post-marketing reports of hepatotoxicity and nephrotoxicity 1
The majority of gastrointestinal side effects (70-80%) occur within the first 2 weeks and are mild to moderate, with 60-65% resolving within the first month 1. This temporal pattern should guide patient counseling and early management strategies.